5-Hydroxytryptamine(2C) receptor activation inhibits 5- hydroxytryptamine(1B)-like receptor function via arachidonic acid metabolism

Kelly A Berg, Saul Maayani, William P Clarke

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We previously reported that in Chinese hamster ovary (CHO) cells, 5- hydroxytryptamine (5-HT)(1B)-like (CHO/5-HT(1B)) receptor-mediated inhibition of forskolin-stimulated cAMP accumulation is inhibited by activation of transfected human 5-HT(2C) receptors but not 5-HT(2A) receptors. In the current study, we investigated the mechanism involved in the regulation of receptor-mediated inhibition of adenylyl cyclase as a means to further elucidate differences between the signal transduction cascades of the 5- HT(2A) and 5-HT(2C) receptor subtypes. Activation of 5-HT(2C) receptors with 5-HT or (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane increased release of arachidonic acid via a phospholipase A2 (PLA2)-dependent mechanism. Incubation with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1 μM) abolished 5-carboxamidotryptamine (5 nM)-mediated inhibition of forskolin- stimulated cAMP accumulation, which was blocked by the PLA2 inhibitor mepacrine (100 μM) and the cyclooxygenase inhibitor indomethacin (2 μM). Furthermore, purinergic receptor-mediated PLA2 activation as well as direct activation of PLA2 with melittin reduced CHO/5-HT(1B) responsiveness. These data indicate that activation of the PLA2/arachidonic acid signaling cascade mediates 5-HT(2C) receptor regulation of the CHO/5-HT(1B) receptor pathway. Consistent with our previous report and in contrast to activation of 5- HT(2C) or purinergic receptors, activation of 5-HT(2A) receptors had no effect on CHO/5-HT(1B) receptor function, although 5-HT(2A) receptor-mediated activation of PLA2 was measured. Interestingly, purinergic receptor-mediated inhibition of CHO/5-HT(1B) receptor function was blocked when 5-HT(2A) receptors were activated simultaneously. These data suggest that the lack of 5-HT(2A)-mediated regulation of CHO/5-HT(1B) receptors may be due to activation of a third pathway (in addition to PLC and PLA2 pathways), which results in the inhibition of the production or the actions of a cyclooxygenase-dependent arachidonic acid metabolite.

Original languageEnglish (US)
Pages (from-to)1017-1023
Number of pages7
JournalMolecular Pharmacology
Volume50
Issue number4
StatePublished - Oct 1996

Fingerprint

Receptor, Serotonin, 5-HT1B
Serotonin Receptors
Arachidonic Acid
Cricetulus
Phospholipases A2
Ovary
Serotonin
Purinergic Receptors
Colforsin
Receptor, Serotonin, 5-HT2C
Melitten
Quinacrine
Cyclooxygenase 2 Inhibitors
Prostaglandin-Endoperoxide Synthases
Adenylyl Cyclases
Indomethacin
Signal Transduction

ASJC Scopus subject areas

  • Pharmacology

Cite this

5-Hydroxytryptamine(2C) receptor activation inhibits 5- hydroxytryptamine(1B)-like receptor function via arachidonic acid metabolism. / Berg, Kelly A; Maayani, Saul; Clarke, William P.

In: Molecular Pharmacology, Vol. 50, No. 4, 10.1996, p. 1017-1023.

Research output: Contribution to journalArticle

@article{581a68706ec546b686e55b7f050fef7c,
title = "5-Hydroxytryptamine(2C) receptor activation inhibits 5- hydroxytryptamine(1B)-like receptor function via arachidonic acid metabolism",
abstract = "We previously reported that in Chinese hamster ovary (CHO) cells, 5- hydroxytryptamine (5-HT)(1B)-like (CHO/5-HT(1B)) receptor-mediated inhibition of forskolin-stimulated cAMP accumulation is inhibited by activation of transfected human 5-HT(2C) receptors but not 5-HT(2A) receptors. In the current study, we investigated the mechanism involved in the regulation of receptor-mediated inhibition of adenylyl cyclase as a means to further elucidate differences between the signal transduction cascades of the 5- HT(2A) and 5-HT(2C) receptor subtypes. Activation of 5-HT(2C) receptors with 5-HT or (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane increased release of arachidonic acid via a phospholipase A2 (PLA2)-dependent mechanism. Incubation with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1 μM) abolished 5-carboxamidotryptamine (5 nM)-mediated inhibition of forskolin- stimulated cAMP accumulation, which was blocked by the PLA2 inhibitor mepacrine (100 μM) and the cyclooxygenase inhibitor indomethacin (2 μM). Furthermore, purinergic receptor-mediated PLA2 activation as well as direct activation of PLA2 with melittin reduced CHO/5-HT(1B) responsiveness. These data indicate that activation of the PLA2/arachidonic acid signaling cascade mediates 5-HT(2C) receptor regulation of the CHO/5-HT(1B) receptor pathway. Consistent with our previous report and in contrast to activation of 5- HT(2C) or purinergic receptors, activation of 5-HT(2A) receptors had no effect on CHO/5-HT(1B) receptor function, although 5-HT(2A) receptor-mediated activation of PLA2 was measured. Interestingly, purinergic receptor-mediated inhibition of CHO/5-HT(1B) receptor function was blocked when 5-HT(2A) receptors were activated simultaneously. These data suggest that the lack of 5-HT(2A)-mediated regulation of CHO/5-HT(1B) receptors may be due to activation of a third pathway (in addition to PLC and PLA2 pathways), which results in the inhibition of the production or the actions of a cyclooxygenase-dependent arachidonic acid metabolite.",
author = "Berg, {Kelly A} and Saul Maayani and Clarke, {William P}",
year = "1996",
month = "10",
language = "English (US)",
volume = "50",
pages = "1017--1023",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - 5-Hydroxytryptamine(2C) receptor activation inhibits 5- hydroxytryptamine(1B)-like receptor function via arachidonic acid metabolism

AU - Berg, Kelly A

AU - Maayani, Saul

AU - Clarke, William P

PY - 1996/10

Y1 - 1996/10

N2 - We previously reported that in Chinese hamster ovary (CHO) cells, 5- hydroxytryptamine (5-HT)(1B)-like (CHO/5-HT(1B)) receptor-mediated inhibition of forskolin-stimulated cAMP accumulation is inhibited by activation of transfected human 5-HT(2C) receptors but not 5-HT(2A) receptors. In the current study, we investigated the mechanism involved in the regulation of receptor-mediated inhibition of adenylyl cyclase as a means to further elucidate differences between the signal transduction cascades of the 5- HT(2A) and 5-HT(2C) receptor subtypes. Activation of 5-HT(2C) receptors with 5-HT or (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane increased release of arachidonic acid via a phospholipase A2 (PLA2)-dependent mechanism. Incubation with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1 μM) abolished 5-carboxamidotryptamine (5 nM)-mediated inhibition of forskolin- stimulated cAMP accumulation, which was blocked by the PLA2 inhibitor mepacrine (100 μM) and the cyclooxygenase inhibitor indomethacin (2 μM). Furthermore, purinergic receptor-mediated PLA2 activation as well as direct activation of PLA2 with melittin reduced CHO/5-HT(1B) responsiveness. These data indicate that activation of the PLA2/arachidonic acid signaling cascade mediates 5-HT(2C) receptor regulation of the CHO/5-HT(1B) receptor pathway. Consistent with our previous report and in contrast to activation of 5- HT(2C) or purinergic receptors, activation of 5-HT(2A) receptors had no effect on CHO/5-HT(1B) receptor function, although 5-HT(2A) receptor-mediated activation of PLA2 was measured. Interestingly, purinergic receptor-mediated inhibition of CHO/5-HT(1B) receptor function was blocked when 5-HT(2A) receptors were activated simultaneously. These data suggest that the lack of 5-HT(2A)-mediated regulation of CHO/5-HT(1B) receptors may be due to activation of a third pathway (in addition to PLC and PLA2 pathways), which results in the inhibition of the production or the actions of a cyclooxygenase-dependent arachidonic acid metabolite.

AB - We previously reported that in Chinese hamster ovary (CHO) cells, 5- hydroxytryptamine (5-HT)(1B)-like (CHO/5-HT(1B)) receptor-mediated inhibition of forskolin-stimulated cAMP accumulation is inhibited by activation of transfected human 5-HT(2C) receptors but not 5-HT(2A) receptors. In the current study, we investigated the mechanism involved in the regulation of receptor-mediated inhibition of adenylyl cyclase as a means to further elucidate differences between the signal transduction cascades of the 5- HT(2A) and 5-HT(2C) receptor subtypes. Activation of 5-HT(2C) receptors with 5-HT or (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane increased release of arachidonic acid via a phospholipase A2 (PLA2)-dependent mechanism. Incubation with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1 μM) abolished 5-carboxamidotryptamine (5 nM)-mediated inhibition of forskolin- stimulated cAMP accumulation, which was blocked by the PLA2 inhibitor mepacrine (100 μM) and the cyclooxygenase inhibitor indomethacin (2 μM). Furthermore, purinergic receptor-mediated PLA2 activation as well as direct activation of PLA2 with melittin reduced CHO/5-HT(1B) responsiveness. These data indicate that activation of the PLA2/arachidonic acid signaling cascade mediates 5-HT(2C) receptor regulation of the CHO/5-HT(1B) receptor pathway. Consistent with our previous report and in contrast to activation of 5- HT(2C) or purinergic receptors, activation of 5-HT(2A) receptors had no effect on CHO/5-HT(1B) receptor function, although 5-HT(2A) receptor-mediated activation of PLA2 was measured. Interestingly, purinergic receptor-mediated inhibition of CHO/5-HT(1B) receptor function was blocked when 5-HT(2A) receptors were activated simultaneously. These data suggest that the lack of 5-HT(2A)-mediated regulation of CHO/5-HT(1B) receptors may be due to activation of a third pathway (in addition to PLC and PLA2 pathways), which results in the inhibition of the production or the actions of a cyclooxygenase-dependent arachidonic acid metabolite.

UR - http://www.scopus.com/inward/record.url?scp=0029661960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029661960&partnerID=8YFLogxK

M3 - Article

C2 - 8863849

AN - SCOPUS:0029661960

VL - 50

SP - 1017

EP - 1023

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -